ADIL Relative Valuation
ADIL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADIL is overvalued; if below, it's undervalued.
Historical Valuation
Adial Pharmaceuticals Inc (ADIL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.66. The fair price of Adial Pharmaceuticals Inc (ADIL) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.32
Fair
-0.77
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Adial Pharmaceuticals Inc. (ADIL) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.76. The thresholds are as follows: Strongly Undervalued below -4.00, Undervalued between -4.00 and -2.38, Fairly Valued between 0.86 and -2.38, Overvalued between 0.86 and 2.48, and Strongly Overvalued above 2.48. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.29
EV/EBIT
Adial Pharmaceuticals Inc. (ADIL) has a current EV/EBIT of -0.29. The 5-year average EV/EBIT is -1.07. The thresholds are as follows: Strongly Undervalued below -3.52, Undervalued between -3.52 and -2.29, Fairly Valued between 0.16 and -2.29, Overvalued between 0.16 and 1.39, and Strongly Overvalued above 1.39. The current Forward EV/EBIT of -0.29 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Adial Pharmaceuticals Inc. (ADIL) has a current PS of 0.00. The 5-year average PS is 21509.22. The thresholds are as follows: Strongly Undervalued below -133198.85, Undervalued between -133198.85 and -55844.82, Fairly Valued between 98863.25 and -55844.82, Overvalued between 98863.25 and 176217.29, and Strongly Overvalued above 176217.29. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Adial Pharmaceuticals Inc. (ADIL) has a current P/OCF of 0.00. The 5-year average P/OCF is 12.70. The thresholds are as follows: Strongly Undervalued below -183.22, Undervalued between -183.22 and -85.26, Fairly Valued between 110.66 and -85.26, Overvalued between 110.66 and 208.61, and Strongly Overvalued above 208.61. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Adial Pharmaceuticals Inc. (ADIL) has a current P/FCF of 0.00. The 5-year average P/FCF is -75.19. The thresholds are as follows: Strongly Undervalued below -367.92, Undervalued between -367.92 and -221.56, Fairly Valued between 71.17 and -221.56, Overvalued between 71.17 and 217.53, and Strongly Overvalued above 217.53. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Adial Pharmaceuticals Inc (ADIL) has a current Price-to-Book (P/B) ratio of 1.67. Compared to its 3-year average P/B ratio of 1.77 , the current P/B ratio is approximately -5.86% higher. Relative to its 5-year average P/B ratio of 4.01, the current P/B ratio is about -58.45% higher. Adial Pharmaceuticals Inc (ADIL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -151.33%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -106.88% , the current FCF yield is about -100.00% lower.
1.73
P/B
Median3y
1.77
Median5y
4.01
-87.61
FCF Yield
Median3y
-151.33
Median5y
-106.88
Competitors Valuation Multiple
The average P/S ratio for ADIL's competitors is 0.00, providing a benchmark for relative valuation. Adial Pharmaceuticals Inc Corp (ADIL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADIL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ADIL in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Adial Pharmaceuticals Inc (ADIL) currently overvalued or undervalued?
What is Adial Pharmaceuticals Inc (ADIL) fair value?
How does ADIL's valuation metrics compare to the industry average?
What is the current P/B ratio for Adial Pharmaceuticals Inc (ADIL) as of Dec 05 2025?
What is the current FCF Yield for Adial Pharmaceuticals Inc (ADIL) as of Dec 05 2025?
What is the current Forward P/E ratio for Adial Pharmaceuticals Inc (ADIL) as of Dec 05 2025?